Allergy Therapeutics (LON:AGY) Hits New 12-Month Low – Time to Sell?

Allergy Therapeutics plc (LON:AGY)’s share price hit a new 52-week low during trading on Wednesday. The company traded as low as GBX 4.50 and last traded at GBX 4.50, with a volume of 1800 shares trading hands. The stock had previously closed at GBX 4.75.

Allergy Therapeutics Trading Down 5.3%

The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58. The stock has a 50 day simple moving average of GBX 5.32 and a 200-day simple moving average of GBX 7.75. The firm has a market cap of £284.96 million, a P/E ratio of -4.64, a P/E/G ratio of -30.70 and a beta of 0.83.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.